Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion type Assertion NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_head.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion description "[For defined tumor types, expression of at least one of the SSX family members was most frequently observed in head and neck cancer (75%), followed by ovarian cancer (50%), malignant melanoma (43%), lymphoma (36%), colorectal cancer (27%) and breast cancer (23%), while leukemias and the few cases of leiomyosarcomas, seminomas and thyroid cancers were found not to express any SSX gene.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_provenance.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion evidence source_evidence_literature NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_provenance.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion SIO_000772 9639388 NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_provenance.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion wasDerivedFrom befree-2016 NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_provenance.
- NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_assertion wasGeneratedBy ECO_0000203 NP1397989.RAxigitM-5vnFLeMnrXqK1d81RSFOS1yc-MW2Ho-HgytQ130_provenance.